Stelexis BioSciences Announces Positive Phase 1 Data for Eganelisib in Relapsed/Refractory AML and Higher-Risk MDS in an Oral Presentation at ASCO 2026

Eganelisib induced complete remissions and hematologic improvements as a single-agent via myeloid differentiation in a Phase 1 study in relapsed/refractory patients with myeloid malignancies (MDS/AML) who show high expression of PI3K-gamma in bone marrow blasts. The improved overall...

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.